# Thylacine Biotherapeutics Inc — Form D

Thylacine Biotherapeutics Inc of MIAMI BEACH, FL, a company, filed a Form D exempt-offering notice with the SEC on 2023-01-19. The offering totals $1.0M, of which $476K was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2023-01-19
- Form: D
- Accession: 0001962783-23-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $1.0M
- Amount sold: $476K
- Remaining: $524K
- Minimum investment: $5K
- Investors: 13
- Date of first sale: 2023-01-05
- Security types: equity, debt
- Revenue range: No Revenues
- SEC file number: 021-471173

## Issuer

- Name: Thylacine Biotherapeutics Inc
- CIK: 0001962783
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 6899 COLLINS AVE, MIAMI BEACH, FL, 33141
- Phone: 6503021392

## Officers, directors & promoters (4)

| Name | Role | Location |
| --- | --- | --- |
| Andrew Fradkin | Director | Ketchum, ID |
| Daniel Graifman | Director | Miami Beach, FL |
| Robert Graifman | Director | Miami Beach, FL |
| Daniel Graifman | Executive Officer | Miami Beach, FL |

## More

- [CIK 1962783 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1962783&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001962783-23-000001.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.